Literature DB >> 687506

Liver size and indices of drug metabolism in epileptics.

H I Pirttiaho, E A Sotaniemi, J T Ahokas, U Pitkänen.   

Abstract

1 The relationship between liver size and in vivo (antipyrine kinetics) and in vitro (cytochrome P-450) drug metabolism was investigated in twenty-one epileptics on long-term anticonvulsant therapy and in controls. 2 The epileptics exhibited significant enlargement of the liver and enhancement of drug metabolism compared to the controls. 3 Liver size correlated to antipyrine kinetics only in controls. Concentration of cytochrome P-450 in liver biopsy specimens correlated with liver size neither in controls nor in epileptics. 4 The total hepatic cytochrome P-450, estimated on the basis of liver weight and cytochrome P-450 concentration of biopsy samples, correlated linearly with antipyrine kinetics, except in patients with the most severely disturbed liver architecture. 5 Measurement of liver size is essential when comparing in vivo and in vitro drug metabolism, but the changes in liver histology are also of great importance.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 687506      PMCID: PMC1429461          DOI: 10.1111/j.1365-2125.1978.tb04597.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  21 in total

1.  EFFECT OF DRUGS ON THE FORMATION OF SMOOTH ENDOPLASMIC RETICULUM AND DRUG-METABOLIZING ENZYMES.

Authors:  H REMMER; H J MERKER
Journal:  Ann N Y Acad Sci       Date:  1965-03-12       Impact factor: 5.691

2.  Phenobarbital markedly increases liver weight in Walker carcinosarcoma bearing rats.

Authors:  R KATO; G FRONTINO; P VASSANELLI
Journal:  Experientia       Date:  1963-01-15

3.  The fate of antipyrine in man.

Authors:  B B BRODIE; J AXELROD
Journal:  J Pharmacol Exp Ther       Date:  1950-01       Impact factor: 4.030

4.  Pharmacological implications of microsomal enzyme induction.

Authors:  A H Conney
Journal:  Pharmacol Rev       Date:  1967-09       Impact factor: 25.468

5.  Drug metabolism and androgen control therapy in prostatic cancer.

Authors:  E A Sotaniemi; M J Kontturi; T K Larmi
Journal:  Clin Pharmacol Ther       Date:  1973 May-Jun       Impact factor: 6.875

Review 6.  Effects of liver disease on drug disposition in man.

Authors:  G R Wilkinson; S Schenker
Journal:  Biochem Pharmacol       Date:  1976-12-15       Impact factor: 5.858

7.  Liver size and indices of drug metabolism in alcoholics.

Authors:  H I Pirttiaho; E A Sotaniemi; J Ahlqvist; U Pitkänen; R O Pelkonen
Journal:  Eur J Clin Pharmacol       Date:  1978-03-17       Impact factor: 2.953

8.  Liver growth and mixed-function oxidase activity: dose-dependent stimulatory and inhibitory effects of alpha-hexachlorocyclohexane.

Authors:  R Schulte-Hermann; C Leberl; H Landgraf; W Koransky
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1974       Impact factor: 3.000

9.  Drug metabolism in epileptics: in vivo and in vitro correlations.

Authors:  E A Sotaniemi; R O Pelkonen; J Ahokas; H I Pirttiaho; J Ahlqvist
Journal:  Br J Clin Pharmacol       Date:  1978-01       Impact factor: 4.335

10.  The relationship between liver volume, antipyrine clearance and indocyanine green clearance before and after phenobarbitone administration in man.

Authors:  C J Roberts; L Jackson; M Halliwell; R A Branch
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335

View more
  12 in total

Review 1.  Pharmacokinetic drug interactions with phenytoin (Part II).

Authors:  R L Nation; A M Evans; R W Milne
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

Review 2.  Case examples of an evaluation of the human relevance of the pyrethroids/pyrethrins-induced liver tumours in rodents based on the mode of action.

Authors:  Tomoya Yamada
Journal:  Toxicol Res (Camb)       Date:  2018-01-16       Impact factor: 3.524

Review 3.  Human relevance of rodent liver tumour formation by constitutive androstane receptor (CAR) activators.

Authors:  Brian G Lake
Journal:  Toxicol Res (Camb)       Date:  2018-03-12       Impact factor: 3.524

4.  Age-related changes in liver size and hepatic blood flow. The influence on drug metabolism in the elderly.

Authors:  K W Woodhouse; H A Wynne
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

Review 5.  Clinical implications of enzyme induction and enzyme inhibition.

Authors:  B K Park; A M Breckenridge
Journal:  Clin Pharmacokinet       Date:  1981 Jan-Feb       Impact factor: 6.447

6.  Disposition of antipyrine and phenytoin correlated with age and liver volume in man.

Authors:  B Bach; J M Hansen; J P Kampmann; S N Rasmussen; L Skovsted
Journal:  Clin Pharmacokinet       Date:  1981 Sep-Oct       Impact factor: 6.447

7.  Roles of hepatic blood flow and enzyme activity in the kinetics of propranolol and sotalol.

Authors:  H I Pirttiaho; E A Sotaniemi; R O Pelkonen; U Pitkänen; M Anttila; H Sundqvist
Journal:  Br J Clin Pharmacol       Date:  1980-04       Impact factor: 4.335

8.  Serum low-density lipoprotein and high-density lipoprotein cholesterol, and liver size in subjects on drugs inducing hepatic microsomal enzymes.

Authors:  P V Luoma; E A Sotaniemi; R O Pelkonen; H I Pirttiaho
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

9.  Hepatic blood flow and drug metabolism in patients on enzyme-inducing anticonvulsants.

Authors:  H I Pirttiaho; E A Sotaniemi; R O Pelkonen; U Pitkänen
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

10.  Renal elimination of the hypoxic cell radiosensitizer misonidazole in Wistar rats: influence of some drugs on its excretion.

Authors:  G Akel; P Canal; G Soula
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1985 Jul-Sep       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.